Editor’s note: This is a developing news story. Please check back soon for updates.
A dual VEGF-A and angiopoietin-2 inhibitor provided fast, durable treatment for wet age-related macular degeneration in a phase 2a study, according to a press release from NovaBridge.
NovaBridge and subsidiary Visara announced topline results from the phase 2a study of VIS-101 for the treatment of wet AMD. VIS-101 is a dual VEGF-A and ANG-2 inhibitor designed to provide more binding sites and increase VEGF-A and ANG-2 affinity, according to the release.
In the study, 38 patients in China with wet AMD were